Navigation Links
Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Date:12/10/2009

TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009. The presentation is scheduled for 3:35 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through January 15, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.


Contact Information:

Peter Dworkin                  Laura Lindsay
Investor Relations             Media Relations
914.345.7640                   914.345.7800
peter.dworkin@regeneron.com    laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... -- Today Eli Lilly and Company (NYSE: ... program to increase the global supply of medicines for ... Lilly donating manufacturing technology and know-how for two antibiotics ... India , Russia ... all MDR-TB ,hot spots., It also served as the ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014  In the last ... parts of Africa to a worldwide crisis ... down with the virus and died, and two nurses were infected. ... how this could happen, the use of modern technology, such as ... went largely unnoticed. This week, InformationWeek Healthcare Editor ...
Breaking Medicine Technology:CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... ROCKVILLE, Md., July 6 A procedure that sends targeted ... to treat a common type of irregular heartbeat, but little ... methods and circumstances for applying it, according to a new ... , , The report examines the use of a ...
... The Netherlands, July 6 Three new small and,medium ... - have joined public-private partnership TI Pharma by,participating in ... diseases, have a total budget of nearly 6 million ... formed by Syncom, Synvolux Therapeutics, and,University Medical Center Groningen, ...
Cached Medicine Technology:New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation 2New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation 3New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer of ... more, is currently hosting a sweepstakes on its official ... open to U.S. residents age 18 and over, and ... lucky winner will then be selected at random from ... to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Graphics, coding, ... are synonymous with the craft of web design and ... website. Yet a simpler solution to create a website ... pictures, videos, contact information, customer reviews and Facebook posts ... "It is the next evolution of how a ...
(Date:10/30/2014)... 2014 High efficacy and low ... the medical-grade skin care domain: Cosmederm, the specialty ... potent topical dermatological products, today announces the launch ... with patented COSMEDERM®-7 anti-irritant technology. , Formulated ... and 70%) and a low pH (pH 1.2 ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 PreDiabetes ... PreD Store shoppers with a supply of ... meals to reduce post-meal blood sugar spikes. Learning how ... is an important part of a diabetes prevention plan. ... will receive one complimentary tube of sugardown. The offer ...
(Date:10/30/2014)... Haven, CT (PRWEB) October 30, 2014 ... categories are raising questions about the impact of traditional ... the marketing method most likely to influence a purchasing ... research poll of 525 consumers conducted by radio marketing ... four product categories, isolating the results of respondents who ...
Breaking Medicine News(10 mins):Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
... Most breast cancer surgeons, practices do not follow ... to a new study from researchers at the University ... with other specialists and providing resources and education to ... mantra for multidisciplinary decision-making and care intake for patients, ...
... options for low-risk prostate cancer found that the rates ... most common treatment approaches, although costs can vary considerably. ... Clinical and Economic Review (ICER), a leader in comparative ... for Technology Assessment. Bringing together the ...
... CHILDREN MAY HAVE POORER LUNG FUNCTION ,A new ... midlife may be influenced by several factors, including birth weight, ... Kingdom analyzed health data from 252 patients, all aged 14 ... patients at age 49 to 51. Results showed that several ...
... Energy and Commerce as part of an investigation into preventable ... report recommending further restrictions regarding duty hours for resident physicians ... safety, according to an article published in the January issue ... (JACR). In 2003, the Accreditation Council for ...
... York, NY, January 4, 2010 Knee osteoarthritis (OA) accounts ... Running, although it has proven cardiovascular and other health benefits, ... a study published in the December 2009 issue of ... compared the effects on knee, hip and ankle joint motions ...
... Extremity War Injuries Symposium was held in Washington, D.C., ... surgeons, researchers, experts from governmental agencies, and others to ... Iraq and Afghanistan and to discuss ways to synergize ... summarizing the findings from the symposium is published in ...
Cached Medicine News:Health News:Few breast cancer surgeons follow quality of care standards, U-M study finds 2Health News:Report suggests similar effectiveness among options for managing low-risk prostate cancer 2Health News:Report suggests similar effectiveness among options for managing low-risk prostate cancer 3Health News:News briefs from the January issue of Chest 2Health News:Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors 2Health News:Running shoes may cause damage to knees, hips and ankles 2Health News:Extremity war injuries: More research is needed 2Health News:Extremity war injuries: More research is needed 3
... iVAD*, implantable ventricular assist ... implantable device used by ... and outflow conduits are ... and anatomically positioned to ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
...
Medicine Products: